To evaluate whether the addition of cataract surgery to an intravitreal injection of triamcinolone acetonide markedly increases frequency and spectrum of complications.
Methods
The comparative nonrandomized clinical interventional investigation included a study group of 60 eyes (56 patients) undergoing cataract surgery and additionally receiving an intravitreal injection of about 20 mg of triamcinolone acetonide and a triamcinolone control group of 290 eyes (262 patients) that consecutively received an intravitreal injection of about 20 mg triamcinolone acetonide without cataract surgery. Reasons for intravitreal injection of triamcinolone acetonide were exudative age-related macular degeneration (n = 228; 65%), diffuse diabetic macular edema (n = 94; 27%), central retinal vein occlusion (n = 17; 5%), and branch retinal vein occlusion (n = 11; 3%). Mean follow-up was 8.6±6.8 months. A second control group included 1068 patients (1068 eyes) who consecutively underwent routine cataract surgery without intravitreal injection.
Results
Study group and triamcinolone control group did not vary significantly in best visual acuity during follow-up (p=0.08), final visual acuity at the end of follow-up (p=0.30), maximal intraocular pressure during follow-up (p=0.99), frequency of an intraocular pressure higher than 21 mmHg (p=0.66), and intraocular pressure at the end of follow-up (p=0.06). Postoperative infectious endophthalmitis, wound leakage or other corneal wound healing problems, persisting corneal endothelial decompensation, rhegmatogenous retinal detachment, marked postoperative pain, or a clinically significant decentration of the intraocular lens were not observed. Study group and the non-triamcinolone control group did not vary significantly in the rate of posterior lens capsule rupture (p=0.11), postoperative infectious endophthalmitis, and persisting postoperative corneal endothelial decompensation.
Conclusions
The addition of cataract surgery to an intravitreal injection of triamcinolone acetonide may not markedly increase amount and frequency of side effects and complications of intravitreal triamcinolone acetonide. No safe conclusions can be reached regarding differences in frequency of postoperative infectious endophthalmitis.
MachemerR., SugitaG., TanoY.Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Sod 979; 77: 171–80.
2.
GrahamR.O., PeymanG.A.Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol1974; 92: 149–54.
3.
MachemerR.Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina1996; 16: 166–7.
4.
IshibashiT., MikiK., SorgenteN.Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol1985; 103: 708–11.
5.
PenfoldP.L., GyoryJ.F., HunyorA.B., BillsonF.A.Exudative macular degeneration and intravitreal triamcinolone. Aust NZ J Ophthalmol1995; 23: 293–8.
6.
ChallaJ.K., GilliesM.C., PenfoldP.L.Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol1998; 26: 277–81.
7.
WingateR.J., BeaumontP.E.Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol1999; 27: 431–2.
PenfoldP.L.Intravitreal triamcinolone in recurrence of choroidal neovascularization. Br J Ophthalmol2002; 86: 600–1.
10.
RansonN.T., DanisR.P., CiullaT.A., PrattL.Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol2002; 86: 527–9.
11.
GilliesM.C., SimpsonJ.M., LuoW.A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol2003; 121: 667–73.
12.
SpaideR.F., SorensonJ., MarananL.Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology2003; 110: 1517–25.
13.
JonasJ.B., AkkoyunI., BuddeW.M., KreissigI., DegenringR.F.Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol2004; 122: 218–22.
14.
JonasJ.B., DegenringR.F., KreissigI., FriedemannT., AkkoyunI.Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative non-randomized study. Eye2005 (in press).
15.
JonasJ.B., HaylerJ.K., Panda-JonasS.Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol2000; 84: 1064–7.
16.
Benitez Del Castillo SanchezJ.M., Garcia SanchezJ.Intravitreal injection of triamcinolone acetonide in non infectious uveitis. Arch Soc Esp Oftalmol2001; 76: 661–4.
17.
AntcliffR.J., SpaltonD.J., StanfordM.R.Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology2001; 108: 765–72.
18.
MartidisA., DukerJ.S., PuliafitoC.A.Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol2001; 119: 1380–3.
19.
DegenringR.F., JonasJ.B.Intravitreal injection of triamcinolone acetonide as treatment of chronic uveitis. Br J Ophthalmol2003; 87: 361.
20.
JonasJ.B., HaylerJ.K., SöfkerA., Panda-JonasS.Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma2001; 10: 284–7.
21.
JonasJ.B., HaylerJ.K., SöfkerA., Panda-JonasS.Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol2001; 131: 468–71.
22.
JonasJ.B., SöfkerA.Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol2001; 132: 425–7.
JonasJ.B., KreissigI., SöfkerA., DegenringR.F.Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol2003; 121: 57–61.
25.
GreenbergP.B., MartidisA., RogersA.H.Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol2002; 86: 247–8.
26.
JonasJ.B., KreissigI., DegenringR.F.Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol2002; 240: 782–3.
27.
IpM.S., KumarK.S.Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol2000; 120: 1217–9.
28.
JonasJ.B., HaylerJ.K., Panda-JonasS.Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graefes Arch Clin Exp Ophthalmol2001; 239: 464–5.
29.
JonasJ.B.Intravitreal triamcinolone acetonide as treatment of chronic focal immunologic corneal graft reaction. Graefes Arch Clin Exp Ophthalmol2003; 241: 779–80.
30.
JonasJ.B.Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol2004; 137: 367–8.
31.
AlldredgeC.D., GarretsonB.R.Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina2003; 23: 113–6.
TanoY., SugitaG., AbramsG., MachemerR.Inhibition of intraocular proliferation with intravitreal corticosteroid. Am J Ophthalmol1980; 89: 131–6.
38.
TanoY., ChandlerD., MachemerR.Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol1980; 90: 810–6.
39.
AntoszykA.N., GottliebJ.L., MachemerR., HatchellD.L.The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol1993; 231: 34–40.
40.
DanisR.P., BingamanD.P., YangY., LaddB.Inhibition of pre-retinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology1996; 103: 2099–104.
41.
CiullaT.A., CriswellM.H., DanisRR, HillT.E.Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol2001; 119: 399–404.
42.
PennJ.S., RajaratnamV.S., CollierR.J., ClarkA.F.The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci2001; 42: 283–90.
43.
PenfoldP.L., WongJ.G., GyoryJ., BillsonF.A.Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Exp Ophthalmol2001; 29: 188–92.
44.
MoshfeghiD.M., KaiserP.K., ScottI.U.Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol2003; 136: 791–6.
45.
JonasJ.B., KreissigI., DegenringR.Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol2003; 87: 24–7.
NelsonM.L., TennantM.T., SivalingamA., RegilloC.D., BelmontJ.B., MartidisA.Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina2003; 23: 686–91.
48.
ParkC.H., JaffeG.J., FekratS.Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol2003; 136: 419–25.
49.
ParkeD.W.Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol2003; 136: 918–9.
